Drug Profile
Tanzisertib
Alternative Names: CC-930; JNK CC-930; JNK-930Latest Information Update: 04 Dec 2019
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Class Antifibrotics; Small molecules
- Mechanism of Action JNK mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Discoid lupus erythematosus; Idiopathic pulmonary fibrosis
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol Myers Squibb
- 16 Jul 2012 Celgene Corporation terminates a phase II trial in Discoid lupus erythematosus in USA (NCT01466725)
- 23 Feb 2012 Celgene initiates enrolment in a phase II trial for Discoid lupus erythematosus in the USA (NCT01466725)